U.S. patent application number 12/646023 was filed with the patent office on 2010-06-24 for novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use.
This patent application is currently assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH. Invention is credited to Stefanie Flohr, Wendelin Frick, Heiner Glombik, Hubert Heuer, Gerhard Jaehne, Werner Kramer, Andreas Lindenschmidt, Hans-Ludwig Schafer.
Application Number | 20100160282 12/646023 |
Document ID | / |
Family ID | 26008042 |
Filed Date | 2010-06-24 |
United States Patent
Application |
20100160282 |
Kind Code |
A1 |
Glombik; Heiner ; et
al. |
June 24, 2010 |
NOVEL DIPHENYLAZETIDINONES, PROCESS FOR THEIR PREPARATION,
MEDICAMENTS COMPRISING THESE COMPOUNDS AND THEIR USE
Abstract
Compounds of the formula I, ##STR00001## in which R1, R2, R3,
R4, R5, and R6 have the meanings given in the description, and
their physiologically acceptable salts. The compounds are suitable
for use, for example, as hypolipidemics.
Inventors: |
Glombik; Heiner; (Hofheim,
DE) ; Kramer; Werner; (Mainz-Laubenheim, DE) ;
Flohr; Stefanie; (Eppstein, DE) ; Frick;
Wendelin; (Hunstetten-Beuerbach, DE) ; Heuer;
Hubert; (Schwabenheim, DE) ; Jaehne; Gerhard;
(Frankfurt, DE) ; Lindenschmidt; Andreas; (Bad
Soden, DE) ; Schafer; Hans-Ludwig; (Hochheim,
DE) |
Correspondence
Address: |
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER;LLP
901 NEW YORK AVENUE, NW
WASHINGTON
DC
20001-4413
US
|
Assignee: |
SANOFI-AVENTIS DEUTSCHLAND
GMBH
Frankfurt Am Main
DE
|
Family ID: |
26008042 |
Appl. No.: |
12/646023 |
Filed: |
December 23, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11155109 |
Jun 17, 2005 |
7674773 |
|
|
12646023 |
|
|
|
|
10021502 |
Dec 19, 2001 |
6992067 |
|
|
11155109 |
|
|
|
|
Current U.S.
Class: |
514/210.02 |
Current CPC
Class: |
C07D 205/08 20130101;
A61P 3/10 20180101; A61P 39/06 20180101; A61P 5/50 20180101; A61P
3/06 20180101; A61P 1/16 20180101; A61P 43/00 20180101; A61P 9/10
20180101; C07F 7/1804 20130101 |
Class at
Publication: |
514/210.02 |
International
Class: |
A61K 31/397 20060101
A61K031/397; A61P 9/10 20060101 A61P009/10 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 21, 2000 |
DE |
10064398.1 |
Oct 26, 2001 |
DE |
10152981.3 |
Claims
1-17. (canceled)
18. A pharmaceutical combination comprising at least one compound
chosen from compounds of the formula ##STR00067## and
pharmaceutically acceptable salts and esters thereof, in which R1,
R2, R4, R5, R6 independently of one another are H, F, Cl, Br, I,
CF.sub.3, NO.sub.2, CN, COOH, COO(C.sub.1-C.sub.6)-alkyl,
CONH.sub.2, CONH(C.sub.1-C.sub.6)-alkyl,
CON[(C.sub.1-C.sub.6)-alky].sub.2, (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl or
O--(C.sub.1-C.sub.6)-alkyl, where one, more or all hydrogens in the
alkyl radicals may be replaced by fluorine; or SO.sub.2--NH.sub.2,
SO.sub.2NH(C.sub.1-C.sub.6)-alkyl,
SO.sub.2N[(C.sub.1-C.sub.6)-alkyl].sub.2,
S--(C.sub.1-C.sub.6)-alkyl, S--(CH.sub.2).sub.n-phenyl,
SO--(CH.sub.2).sub.n-phenyl, SO.sub.2--(C.sub.1-C.sub.6)-alkyl or
SO.sub.2--(CH.sub.2).sub.n-phenyl, where n=0-6 and the phenyl
radical may be substituted up to two times by F, Cl, Br, OH,
CF.sub.3, NO.sub.2, CN, OCF.sub.3, O--(C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.6)-alkyl or NH.sub.2; or NH.sub.2,
NH--(C.sub.1-C.sub.6)-alkyl, N((C.sub.1-C.sub.6)-alkyl).sub.2,
NH(C.sub.1-C.sub.7)-acyl, phenyl, O--(CH.sub.2).sub.n-phenyl, where
n=0-6, where the phenyl ring may be mono- to trisubstituted by F,
Cl, Br, I, OH, CF.sub.3, NO.sub.2, CN, OCF.sub.3,
O--(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkyl, NH.sub.2,
NH(C.sub.1-C.sub.6)-alkyl, N((C.sub.1-C.sub.6)-alkyl).sub.2,
SO.sub.2--CH.sub.3, COOH, COO--(C.sub.1-C.sub.6)-alkyl or
CONH.sub.2; (LAG) is a sugar residue, disugar residue, trisugar
residue, tetrasugar residue; a sugar acid, an amino sugar; an amino
acid residue, an oligopeptide residue comprising 2 to 9 amino
acids; a trialkylammoniumalkyl radical; or --O--(SO.sub.2)--OH; and
at least one further pharmacologically active compound, wherein
said at least one further pharmacologically active compound is
chosen from simvastatin, fluvastatin, pravastatin, lovastatin,
atorvastatin, cerivastatin, and rosuvastatin.
19. A pharmaceutical combination according to claim 18, wherein the
at least one further pharmacologically active compound is
atorvastatin.
20. A pharmaceutical combination according to claim 18, wherein the
at least one further pharmacologically active compound is
rosuvastatin.
Description
[0001] This application claims the benefit of priority under 35
U.S.C. .sctn.119(a) to German patent application no. 10064398.1,
filed on Dec. 21, 2000, and German patent application no.
10152981.3, filed on Oct. 26, 2001. The contents of both priority
documents are incorporated by reference herein.
[0002] The invention relates to substituted diphenylazetidinones,
to their physiologically acceptable salts and to derivatives having
physiological function.
[0003] Diphenylazetidinones (such as, for example, ezetimibe) and
their use for treating hyperlipidemia and arteriosclerosis and
hypercholesterolemia have already been described [cf. Drugs of the
Future 2000, 25(7):679-685 and U.S. Pat. No. 5,756,470].
[0004] It was an object of the invention to provide further
compounds having a therapeutically utilizable hypolipidemic action.
In particular, it was an object to find novel compounds which,
compared to the compounds described in the prior art, are absorbed
to a very low extent. Very low absorption is to be understood as
meaning an intestinal absorption of less than 10%, preferably less
than or equal to 5%. In particular, absorption of the novel
compounds should be less than that of ezetimibe. Pharmaceutically
active compounds which are absorbed to a very low extent generally
have considerably fewer side-effects.
[0005] Accordingly, an embodiment of the invention relates to
compounds of the formula I,
##STR00002##
in which [0006] R1, R2, R3, R4, R5, R6 independently of one another
are (C.sub.0-C.sub.30)-alkylene-(LAG), where one or more carbon
atoms of the alkylene radical may be replaced by --O--,
--(C.dbd.O)--, --CH.dbd.CH--, --N((C.sub.1-C.sub.6)-alkyl)-,
--N((C.sub.1-C.sub.6)-alkylpenyl) or --NH--; or [0007] H, F, Cl,
Br, I, CF.sub.3, NO.sub.2, CN, COOH, COO(C.sub.1-C.sub.6)-alkyl,
CONH.sub.2, CONH(C.sub.1-C.sub.6)-alkyl,
CON[(C.sub.1-C.sub.6)-alkyl].sub.2, (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl or
O--(C.sub.1-C.sub.6)-alkyl, where one, more or all hydrogens in the
alkyl radicals may be replaced by fluorine; or [0008]
SO.sub.2--NH.sub.2, SO.sub.2NH(C.sub.1-C.sub.6)-alkyl,
SO.sub.2N[(C.sub.1-C.sub.6)-alkyl].sub.2,
S--(C.sub.1-C.sub.6)-alkyl, S--(CH.sub.2).sub.n-phenyl,
SO--(C.sub.1-C.sub.6)-alkyl, SO--(CH.sub.2).sub.n-phenyl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl or
SO.sub.2--(CH.sub.2).sub.n-phenyl, where n=0-6 and the phenyl
radical may be substituted up to two times by F, Cl, Br, OH,
CF.sub.3, NO.sub.2, CN, OCF.sub.3, O--(C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.6)-alkyl or NH.sub.2; or [0009] NH.sub.2,
NH--(C.sub.1-C.sub.6)-alkyl, N((C.sub.1-C.sub.6)-alkyl).sub.2,
NH(C.sub.1-C.sub.7)-acyl, phenyl or O--(CH.sub.2).sub.n-phenyl,
where n=0-6, where the phenyl ring may be mono- to trisubstituted
by F, Cl, Br, I, OH, CF.sub.3, NO.sub.2, CN, OCF.sub.3,
O--(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkyl, NH.sub.2,
NH(C.sub.1-C.sub.6)-alkyl, N((C.sub.1-C.sub.6)-alkyl).sub.2,
SO.sub.2--CH.sub.3, COOH, COO--(C.sub.1-C.sub.6)-alkyl or
CONH.sub.2; [0010] (LAG) is a sugar residue, disugar residue,
trisugar residue, tetrasugar residue; [0011] a sugar acid, an amino
sugar; [0012] an amino acid residue, an oligopeptide residue
comprising 2 to 9 amino acids; or [0013] a trialkylammoniumalkyl
radical; or --O--(SO.sub.2)--OH; wherein at least one of the
radicals R1 or R6 has the meaning
(C.sub.0-C.sub.30)-alkylene-(LAG), where one or more carbon atoms
of the alkylene radical may be replaced by --O--, --(C.dbd.O)--,
--CH.dbd.CH--, --C.ident.C--, --N((C.sub.1-C.sub.6)-alkyl)-,
--N((C.sub.1-C.sub.6)-alkylpenyl) or --NH--, and where the radicals
R1 and R2 may not have the meaning --O-sugar residue or --O-sugar
acid, and its pharmaceutically acceptable salts.
[0014] Another embodiment of the invention relates to compounds of
the formula I, in which at least one of the radicals R1 to R6 has
the meaning (C.sub.0-C.sub.30)-alkylene-(LAG), where one or more
carbon atoms of the alkylene radical may be replaced by --O--,
--(C.dbd.O)--, --N((C.sub.1-C.sub.6)-alkyl)-, or --NH--.
[0015] Another embodiment of the invention relates to compounds of
the formula I, in which one of the radicals R1 or R3 has the
meaning (C.sub.0-C.sub.30)-alkylene-(LAG), where one or more carbon
atoms of the alkylene radicals may be replaced by --O--,
--(C.dbd.O)--, --N(CH.sub.3)--, or --NH--.
[0016] Another embodiment of the invention relates to compounds of
the formula I, in which one of the radicals R1 or R3 has the
meaning
--(CH.sub.2).sub.0-1--NH--(C.dbd.O).sub.0-1--(C.sub.0-C.sub.25)-alkylene--
(C.dbd.O).sub.0-1--N(R7).sub.0-1-(LAG); where one or more carbon
atoms of the alkylene radical may be replaced by oxygen atoms and
where R7 is H or CH.sub.3.
[0017] Another embodiment of the invention relates to compounds of
the formula I in which the group LAG is a monosugar residue.
[0018] A trialkylammonium alkyl radical is to be understood as
meaning the following group
##STR00003##
in which n=0 to 10 and Alk.sub.1, Alk.sub.2, Alk.sub.3
independently of one another each denote a straight-chain or
branched alkyl radical having 1 to 20 carbon atoms.
[0019] Owing to their increased solubility in water, compared to
the parent compounds, pharmaceutically acceptable salts are
particularly suitable for medical applications. These salts should
have a pharmaceutically acceptable anion or cation. Suitable
pharmaceutically acceptable acid addition salts of the compounds
according to the invention are salts of inorganic acids, such as
hydrochloric acid, hydrobromic acid, phosphoric acid,
metaphosphoric acid, nitric acid, sulfonic acid and sulfuric acid,
and of organic acids, such as acetic acid, benzenesulfonic acid,
benzoic acid, citric acid, ethanesulfonic acid, fumaric acid,
gluconic acid, glycolic acid, isothionic acid, lactic acid,
lactobionic acid, maleic acid, malic acid, methanesulfonic acid,
succinic acid, p-toluenesulfonic acid, tartaric acid and
trifluoroacetic acid, for example. For medical purposes, very
particular preference is given to using the chloride salt. Suitable
pharmaceutically acceptable basic salts are ammonium salts, alkali
metal salts (such as sodium and potassium salts) and alkaline earth
metal salts (such as magnesium and calcium salts).
[0020] The scope of the invention also includes salts having a
pharmaceutically unacceptable anion, which salts may be useful
intermediates for preparing or purifying pharmaceutically
acceptable salts and/or for use in nontherapeutic, for example in
vitro, applications.
[0021] Here, the term "derivative having physiological function"
refers to any physiologically acceptable derivative of a compound
according to the invention, for example an ester, capable of
forming, upon administration to a mammal, for example man, to form
such a compound or an active metabolite (directly or
indirectly).
[0022] A further aspect of this invention are prodrugs of the
compounds according to the invention. Such prodrugs can be
metabolized in vivo to give a compound according to the invention.
These prodrugs may or may not be active in their own right.
[0023] The compounds according to the invention can also be present
in various polymorphous forms, for example as amorphous and
crystalline polymorphous forms. The scope of the invention includes
all polymorphous forms of the compounds according to the invention,
which form a further aspect of the invention. The compounds of the
invention may also exist in the form of solvates.
[0024] The compounds of the formula I and their pharmaceutically
acceptable salts, esters and prodrugs and derivatives having
physiological function are ideal medicaments for treating an
impaired lipid metabolism, in particular hyperlipidemia. The
compounds of the formula I are also suitable for modulating the
serum cholesterol concentration and for treating arteriosclerotic
manifestations. The compounds of the invention are also suitable
for the treatment of insulin resistance.
[0025] As used here, "treatment" or "therapy" of a condition and
"treating" a condition can mean successfully eliminating the
condition, reducing the effects associated with it, and/or reducing
its severity. It also includes administering the relevant compounds
to a patient to avoid recurrence of a condition. It also includes
avoiding the onset of a condition by administering the relevant
compounds to patients falling into a risk group or category for
developing the particular condition. Those skilled in the art can
routinely identify patients likely to present with a given
condition, thereby qualifying as candidates for treatment.
[0026] The compound(s) of the formula (I) can also be administered
in combination with other active compounds.
[0027] The amount of a compound of the formula (I) required to
achieve the desired biological effect depends on a number of
factors, for example on the specific compound chosen, on the
intended use, on the mode of administration and on the clinical
condition of the patient. In general, the daily dose is in the
range from 0.1 mg to 100 mg (typically from 0.1 mg to 50 mg) per
day per kilogram of bodyweight, for example 0.1-10 mg/kg/day.
Tablets or capsules may contain, for example, from 0.01 to 100 mg,
typically from 0.02 to 50 mg. In the case of pharmaceutically
acceptable salts, the abovementioned weight data relate to the
weight of the diphenyl-azetidinone-ion derived from the salt. For
the therapy of the above-mentioned conditions, the compounds of the
formula (I) can be used themselves as the compound, but preferably
they are present in the form of a pharmaceutical composition with
an acceptable carrier. The carrier must of course be acceptable in
the sense that it is compatible with the other constituents of the
composition and is not harmful to the health of the patient. The
carrier can be a solid or a liquid or both and is preferably
formulated with the compound as an individual dose, for example as
a tablet, which can contain from 0.05% to 95% by weight of the
active compound.
[0028] Further pharmaceutically active substances can also be
present, including further compounds of the formula (I). The
pharmaceutical compositions according to the invention can be
prepared by one of the known pharmaceutical methods, which
essentially consist in mixing the constituents with
pharmacologically acceptable carriers and/or auxiliaries.
[0029] Pharmaceutical compositions according to the invention are
those which are suitable for oral or peroral (e.g. sublingual)
administration, although the most suitable manner of administration
is dependent in each individual case on the nature and severity of
the condition to be treated and on the type of the compound of the
formula (I) used in each case. Coated formulations and coated
delayed-release formulations are also included in the scope of the
invention. Acid-resistant and enteric formulations are preferred.
Suitable enteric coatings include cellulose acetate phthalate,
polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate
and anionic polymers of methacrylic acid and
methylmethacrylate.
[0030] Suitable pharmaceutical compounds for oral administration
can be present in separate units, such as, for example, capsules,
cachets, lozenges or tablets, which in each case contain a specific
amount of the compound of the formula (I); as a powder or granules;
as a solution or suspension in an aqueous or nonaqueous liquid; or
as an oil-in-water or water-in-oil emulsion. As already mentioned,
these compositions can be prepared according to any suitable
pharmaceutical method which includes a step in which the active
compound and the carrier (which can consist of one or more
additional constituents) are brought into contact. In general, the
compositions are prepared by uniform and homogeneous mixing of the
active compound with a liquid and/or finely divided solid carrier,
after which the product, if necessary, is shaped. For example, a
tablet can thus be prepared by pressing or shaping a powder or
granules of the compound, if appropriate with one or more
additional constituents. Pressed tablets can be produced by
tableting the compound in free-flowing form, such as, for example,
a powder or granules, if appropriate mixed with a binder,
lubricant, inert diluent and/or a (number of)
surface-active/dispersing agent(s) in a suitable machine. Shaped
tablets can be produced by shaping the pulverulent compound
moistened with an inert liquid diluent in a suitable machine.
[0031] Pharmaceutical compositions which are suitable for peroral
(sublingual) administration include lozenges which contain a
compound of the formula (I) with a flavoring, customarily sucrose
and gum arabic or tragacanth, and pastilles which include the
compound in an inert base such as gelatin and glycerol or sucrose
and gum arabic.
[0032] Suitable other active compounds for the combination
preparations include: all antidiabetics, mentioned in Rote Liste
2001, Chapter 12, the disclosure of which is incorporated by
reference herein. They can be combined with the compounds of the
formula I according to the invention in particular to achieve a
synergistically enhanced action. The active compound combination
can be administered either by separate administration of the active
compounds to the patient or in the form of combination preparations
comprising a plurality of active compounds in a pharmaceutical
preparation.
[0033] Antidiabetics include insulin and insulin derivatives, such
as, for example, Lantus.RTM. or HMR 1964, GLP-1 derivatives, such
as, for example, those disclosed by Novo Nordisk A/S in WO
98/08871, the disclosure of which is incorporated by reference
herein, and oral hypoglycemic active compounds.
[0034] The oral hypoglycemic active compounds preferably include
sulfonyl ureas, biguadines, meglitinides, oxadiazolidinediones,
thiazolidinediones, glucosidase inhibitors, glucagon antagonists,
GLP-1 agonists, potassium channel openers, such as, for example,
those disclosed by Novo Nordisk A/S in WO 97/26265 and WO 99/03861,
the disclosures of which are incorporated by reference herein,
insulin sensitizers, inhibitors of liver enzymes involved in
stimulating gluconeogenesis and/or glycogenolysis, modulators of
glucose uptake, compounds which modulate lipid metabolism, such as
antihyperlipidemic active compounds and antilipidemic active
compounds, compounds which reduce food intake, PPAR and PXR
agonists and active compounds which act on the ATP-dependent
potassium channel of the beta cells.
[0035] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an HMGCoA reductase
inhibitor such as simvastatin, fluvastatin, pravastatin,
lovastatin, atorvastatin, cerivastatin, rosuvastatin.
[0036] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a cholesterol
absorption inhibitor, such as, for example, ezetimibe, tiqueside,
pamaqueside.
[0037] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a PPAR gamma
agonist, such as, for example, rosiglitazone, pioglitazone,
JTT-501, GI 262570.
[0038] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a PPAR alpha
agonist, such as, for example, GW 9578, GW 7647.
[0039] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a mixed PPAR
alpha/gamma agonist, such as, for example, GW 1536, AVE 8042, AVE
8134, AVE 0847.
[0040] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a fibrate, such as,
for example, fenofibrate, clofibrate, bezafibrate.
[0041] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an MTP inhibitor,
such as, for example, Bay 13-9952, BMS-201038, R-103757.
[0042] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a bile acid
absorption inhibitor, such as, for example, HMR 1453.
[0043] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a CETP inhibitor,
such as, for example, Bay 194789.
[0044] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a polymeric bile
acid adsorber, such as, for example, cholestyramine,
colesolvam.
[0045] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an LDL receptor
inducer, such as, for example, HMR1171, HMR1586.
[0046] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an ACAT inhibitor,
such as, for example, avasimibe.
[0047] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an antioxidant, such
as, for example, OPC-14117.
[0048] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a lipoprotein lipase
inhibitor, such as, for example, NO-1886.
[0049] In one embodiment of the invention, the compounds of the
formula I are administered in combination with an ATP citrate lyase
inhibitor, such as, for example, SB-204990.
[0050] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a squalene
synthetase inhibitor, such as, for example, BMS-188494.
[0051] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a lipoprotein (a)
antagonist, such as, for example, CI-1027 or nicotinic acid.
[0052] In one embodiment of the invention, the compounds of the
formula I are administered in combination with a lipase inhibitor,
such as, for example, Orlistat.
[0053] In one embodiment of the invention, the compounds of the
formula I are administered in combination with insulin.
[0054] In one embodiment, the compounds of the formula I are
administered in combination with a sulfonyl urea, such as, for
example, tolbutamide, glibenclamide, glipizide or gliclazide.
[0055] In one embodiment, the compounds of the formula I are
administered in combination with a biguanide, such as, for example,
metformin.
[0056] In another embodiment, the compounds of the formula I are
administered in combination with a meglitinide, such as, for
example, repaglinide.
[0057] In one embodiment, the compounds of the formula I are
administered in combination with a thiazolidinedione, such as, for
example, troglitazone, ciglitazone, pioglitazone, rosiglitazone, or
the compounds disclosed by Dr. Reddy's Research Foundation in WO
97/41097, the disclosure of which is incorporated by reference
herein, in particular
5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2-
,4-thiazolidinedione.
[0058] In one embodiment, the compounds of the formula I are
administered in combination with an .alpha.-glucosidase inhibitor,
such as, for example, miglitol or acarbose.
[0059] In one embodiment, the compounds of the formula I are
administered in combination with an active compound which acts on
the ATP-dependent potassium channel of beta cells, such as, for
example, tolbutamide, glibenclamide, glipizide, gliazide or
repaglinide.
[0060] In one embodiment, the compounds of the formula I are
administered in combination with more than one of the
abovementioned compounds, for example in combination with a
sulfonyl urea and metformin, a sulfonyl urea and acarbose,
repaglinide and metformin, insulin and a sulfonyl urea, insulin and
metformin, insulin and troglitazon, insulin and lovastatin,
etc.
[0061] In a further embodiment, the compounds of the formula I are
administered in combination with CART agonists, NPY agonists, MC4
agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists,
CRF BP antagonists, urocortin agonists, .beta.3-agonists, MSH
(melanocyte-stimulating hormone) agonists, CCK agonists, serotonin
reuptake inhibitors, mixed serotonin and noradrenergic compounds,
5HT agonists, bombesin agonists, galanin antagonists, growth
hormone, growth hormone-releasing compounds, TRH agonists,
decoupling protein 2- or 3 modulators, leptin agonists, DA agonists
(bromocriptin, doprexin), lipase/amylase inhibitors, PPAR
modulators, RXR modulators or TR-.beta. agonists.
[0062] In one embodiment of the invention, the further active
compound is leptin.
[0063] In one embodiment, the further active compound is
dexamphetamine or amphetamine.
[0064] In one embodiment, the further active compound is
fenfluramine or dexfenfluramine.
[0065] In another embodiment, the further active compound is
sibutramine.
[0066] In one embodiment, the further active compound is
Orlistat.
[0067] In one embodiment, the further active compound is mazindol
or phentermine.
[0068] In one embodiment, the compounds of the formula I are
administered in combination with fiber, preferably insoluble fiber,
such as, for example, Caromax.RTM.. The combination with
Caromax.RTM. can be given in one preparation or by separate
administration of compounds of the formula I and Caromax.RTM..
Here, Caromax.RTM. can also be administered in the form of food,
such as, for example, in bakery goods or muesli bars. Compared to
the individual active compounds, the combination of compounds of
the formula I with Caromax.RTM. is, in addition to an enhanced
action, in particular with respect to the lowering of LDL
cholesterol, also characterized by its improved tolerability.
[0069] It goes without saying that each suitable combination of the
compounds according to the invention with one or more of the
compounds mentioned above and optionally one or more further
pharmacologically active substances is included in the scope of the
present invention.
[0070] The invention furthermore provides both stereoisomer
mixtures of the formula I and the pure stereoisomers of the formula
I, and diastereomer mixtures of the formula I and the pure
diastereomers. The mixtures are separated by chromatographic
means.
[0071] Preference is given to both racemic and enantiomerically
pure compounds of the formula I of the following structure:
##STR00004##
[0072] Sugar residues are to be understood as meaning compounds
which are derived from aldoses and ketoses which have 3 to 7 carbon
atoms and may belong to the D or the L series; also included are
amino sugars, sugar alcohols or sugar acids. Glucose, mannose,
fructose, galactose, ribose, erythrose, glycerolaldehyde,
sedoheptulose, glucosamine, galactosamine, glucuronic acid,
galacturonic acid, gluconic acid, galactonic acid, mannonic acid,
glucamine, 3-amino-1,2-propanediol, glucaric acid and galactaric
acid may be mentioned by way of example.
[0073] Disugars are saccharides composed of two sugar units. Di-,
tri- or tetrasaccharides are formed by acetal-like binding of two
or more sugars. Here, the bonds may be in the .alpha.- or
.beta.-form. Lactose, maltose and cellobiose may be mentioned by
way of example.
[0074] If the sugar is substituted, the substitution is preferably
at the hydrogen atom of an OH group of the sugar.
[0075] Suitable protective groups for the hydroxyl groups of the
sugars are substantially: benzyl, acetyl, benzoyl, pivaloyl,
trityl, tert-butyldimethylsilyl, benzylidene, cyclohexylidene or
isopropylidene protective groups.
[0076] The term "amino acids" or "amino acid residues" refers, for
example, to the stereoisomeric forms, i.e. the D or L forms, of the
following compounds:
TABLE-US-00001 alanine glycine proline cysteine histidine glutamine
aspartic acid isoleucine arginine glutamic acid lysine serine
phenylalanine leucine threonine tryptophan methionine valine
tyrosine asparagine 2-aminoadipic acid 2-aminoisobutyric acid
3-aminoadipic acid 3-aminoisobutyric acid beta-alanine
2-aminopimelic acid 2-aminobutyric acid 2,4-diaminobutyric acid
4-aminobutyric acid desmosine piperidine carboxylic acid
2,2-diaminopimelic acid 6-aminocaproic acid 2,3-diaminopropionic
acid 2-aminoheptanoic acid N-ethylglycine 2-(2-thienyl)glycine
3-(2-thienyl)alanine penicillamine sarcosine N-ethylasparagine
N-methylisoleucine hydroxylysine 6-N-methyllysine
allo-hydroxylysine N-methylvaline 3-hydroxyproline norvaline
4-hydroxyproline norleucine isodesmosine ornithine allo-isoleucine
N-methylglycine
[0077] For abbreviating the amino acids, the conventional notation
was used (cf. Schroder, Lubke, The Peptides, Volume I, New York
1965, pages XXII-XXIII; Houben-Weyl, Methoden der Organischen
Chemie [Methods of organic chemistry], Volume XV/1 and 2, Stuttgart
1974). The amino acid pGlu denotes pyroglutamyl, NaI denotes
3-(2-naphthyl)alanine, azagly-NH.sub.2 denotes a compound of the
formula NH.sub.2--NH--CONH.sub.2 and D-Asp denotes the D form of
aspartic acid. According to their chemical nature, peptides are
acid amides, and on hydrolysis they decompose into amino acids.
[0078] An oligopeptide is to be understood as meaning a peptide
constructed of 2 to 9 of the amino acids mentioned above.
[0079] Suitable protective groups (see, for example, T. W. Greene,
"Protective Groups in Organic Synthesis") for amino acids are
primarily:
Arg(Tos), Arg(Mts), Arg(Mtr), Arg(PMV), Asp(OBzl), Asp(OBut),
Cys(4-MeBzl), Cys(Acm), Cys(SBut), Glu(Obzl), Glu(Obut), His(Tos),
His(Fmoc), His(Dnp), His(Trt), Lys(Cl-Z), Lys(Boc), Met(O),
Ser(Bzl), Ser(But), Thr(Bzl), Thr(But), Trp(Mts), Trp(CHO),
Tyr(Br-Z), Tyr(Bzl) or Tyr(But).
[0080] Amino protective groups that are preferably used are the
benzyloxycarbonyl (Z) radical, which can be removed by catalytic
hydrogenation, the 2-(3,5-dimethyloxyphenyl)propyl
(2)oxycarbonyl(Ddz) or trityl (Trt) radical, which can be removed
by weak acids, and the 9-fluorenylmethyloxycarbonyl (Fmoc) radical,
which can be removed using secondary amines.
[0081] The invention furthermore relates to a process for preparing
diphenylazetidinone derivatives of formula I.
##STR00005##
[0082] Independently of one another, x and y can be from 0 to 10.
In compound II, --(CH.sub.2).sub.x--NH.sub.2 may alternatively also
be attached to one of the other two phenyl rings.
[0083] The process for preparing the compounds of the formula I
comprises reacting an amine of the formula II with an alkylating or
acylating agent which, preferably in the omega position, carries a
further functionality--if appropriate in protected form. This
functionality is (after deprotection) used for attaching (LAG), for
example with the formation of ether, amine or amide bonds.
[0084] The examples below serve to illustrate the invention in more
detail, without limiting the invention to the products and
embodiments described in the examples.
EXAMPLE I
N-4-[3-(3-Hydroxy-3-phenylpropyl)-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]b-
enzyl-5-(2,3,4,5,6-pentahydroxyhexylamino)pentanamide (3)
##STR00006##
[0085] a)
N-4-[3-(3-Hydroxy-3-phenylpropyl)-2-(4-methoxyphenyl)-4-oxoazeti-
din-1-yl]-benzyl-5-bromopentanamide (2)
[0086] 416 mg of
1-(4-aminomethylphenyl)-3-(3-hydroxy-3-phenylpropyl)-4-(4-methoxy-phenyl)-
azetidin-2-one (1) are dissolved in 10 ml of dried dichloromethane,
and 0.2 ml of triethylamine is added. With ice-cooling, 200 mg of
5-bromovaleryl chloride, dissolved in 2 ml of dichloromethane, are
added, and the mixture stirred at room temperature for 5 hours. 5
ml of water are added, the mixture is acidified using 0.5 N HCl (pH
.about.3), the phases are separated, the aqueous phase is washed
with a little dichloromethane, the combined organic solutions are
dried with sodium sulfate and the residue is, after removal of the
solvent, purified by silica gel column filtration. This gives 2 as
an oil of molecular weight 579.54
(C.sub.31H.sub.35BrN.sub.2O.sub.4) MS (FAB): 581/579
(M+H.sup.+)
b)
N-4-[3-(3-Hydroxy-3-phenylpropyl)-2-(4-methoxyphenyl)-4-oxoazetidin-1-y-
l]benzyl-5-(2,3,4,5,6-pentahydroxyhexylamino)pentanamide (3)
[0087] 300 mg of 2 are dissolved in 10 ml of dimethylformamide, and
191 mg of 6-aminohexane-1,2,3,4,5-pentaol are added. The mixture is
stirred at 80.degree. C. until the reaction (monitored by
thin-layer chromatography) has substantially ended (after about 2
hours). The solvent is then removed under reduced pressure and the
residue is chromatographed on silica gel (mobile phase:
CH.sub.2Cl.sub.2/methanol/conc. ammonia=30:10:2). This gives 3 of
molecular weight 679.82 (C.sub.37H.sub.49N.sub.3O.sub.9); MS (FAB):
680 (M+H.sup.+).
EXAMPLE II
N-4-1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-1-oxoazetidi-
n-2-yl}benzyl-2,3,4,5,6-pentahydroxyhexanamide (4)
##STR00007##
[0088] a)
4-[5-(4-Fluorophenyl)-1-(4-fluorophenylamino)-5-hydroxy-2-(2-oxo-
-4-phenyl-oxazolidin-3-carbonyl)pentyl]benzonitrile (5)
[0089] Under argon, 2.5 g of
3-[5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-oxazolidin-2-one
are dissolved in 30 ml of dichloromethane, 3.9 g of
4-[(4-fluoro-phenylimino)methyl]benzonitrile are added and the
mixture is cooled to -10.degree. C. 6.4 ml of diisopropylethylamine
are added to this mixture and then, over a period of 3 min, 4.05 ml
of trimethylsilyl chloride such that the temperature does not
exceed -5.degree. C. At this temperature, the mixture is stirred
for another hour, and it is then cooled to -25.degree. C. 0.8 ml of
titanium tetrachloride is then added slowly. The dark mixture is
stirred at -25 to -30.degree. C. overnight and then decomposed
using 35 ml of 7% strength tartaric acid solution, and stirring is
continued at room temperature for 1 hour. 15 ml of a 20% strength
sodium bicarbonate solution are then added, and the mixture is
stirred for another hour. Following phase separation, the org.
phase is washed with 30 ml of water, dried over magnesium sulfate
and concentrated to about 10 ml. After addition of 2 ml of
bistrimethylsilylacetamide, the mixture is heated at reflux for 30
min and then concentrated under reduced pressure. The residue is
crystallized with ethyl acetate/heptane. The product is filtered
off with suction and dried under reduced pressure. This gives 5 of
molecular weight 653.81 (C.sub.37H.sub.37F.sub.2N.sub.3O.sub.4Si);
MS (ESI+): 654.3 (M+H.sup.+), 582.2
(M+H.sup.+--Si(CH.sub.3).sub.3).
b)
{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidi-
n-2-yl}benzonitrile (6)
[0090] 2 g of 5 are dissolved in 20 ml of methyl tert-butyl ether
and, with 100 mg of tetrabutylammonium fluoride trihydrate and 1.3
ml of bistrimethylsilylacetamide, heated at 40.degree. C. for about
1 h. The reaction is monitored by thin-layer chromatography. After
the reaction has ended, initially 0.2 ml of glacial acetic acid is
added, and the mixture is stirred for 30 min and concentrated. The
residue is treated with 20 ml of a mixture of isopropanol/2N
sulfuric acid=10:1 and stirred for 1 hour. Following the addition
of a spatula tip of solid sodium bicarbonate, the mixture is once
more concentrated under reduced pressure, the residue is taken up
in ethyl acetate, the org. phase is washed with water and dried and
the residue is, after removal of the solvent, purified by column
chromatography (SiO.sub.2, CH.sub.2Cl.sub.2/methanol=100:1). This
gives 6 of molecular weight 418.45
(C.sub.25H.sub.20F.sub.2N.sub.2O.sub.2); MS (DCI+): 419
(M+H.sup.+).
c)
4-(4-Aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydr-
oxypropyl]azetidin-2-one (7)
[0091] 200 mg of 6 are dissolved in 20 ml of ethanol and, with 0.5
ml of conc. ammonia, hydrogenated over Raney nickel at a hydrogen
pressure of 75 bar and at 25.degree. C. for 30 hours. The catalyst
is filtered off with suction, the filtrate is concentrated under
reduced pressure and the residue is purified by column filtration
(SiO.sub.2, CH.sub.2Cl.sub.2/methanol/conc. NH.sub.3=100:10:1).
This gives 7 of molecular weight 422.5
(C.sub.25H.sub.22F.sub.2N.sub.2O.sub.2); MS (DCI+): 423
(M+H.sup.+), 405 (M+H.sup.+--H.sub.2O).
d)
N-4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoaze-
tidin-2-yl}benzyl-2,3,4,5,6-pentahydroxyhexanamide (4)
[0092] 50 mg of 7 and 25 mg of
3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-one are dissolved
in 5 ml of methanol and, together with 10 mg of Na.sub.2CO.sub.3,
stirred overnight. The mixture is filtered off with suction, the
filtrate is concentrated under reduced pressure and the residue is
purified by column filtration (SiO.sub.2,
CH.sub.2Cl.sub.2/methanol=10:1). This gives 4 having a melting
point above 180.degree. C. and the molecular weight 600.6
(C.sub.31H.sub.34F.sub.2N.sub.2O.sub.8); MS (ESI+): 601
(M+H.sup.+), 583 (M+H.sup.+--H.sub.2O).
EXAMPLE III
N-4-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazeti-
din-1-yl]benzyl-12-(2,3,4,5,6-pentahydroxyhexanoylamino)dodecanamide
(8)
##STR00008##
[0093] a) 12-(2,3,4,5,6-Pentahydroxyhexanoylamino)dodecanoic Acid
(9)
[0094] 3.5 g of 12-aminododecanoic acid are dissolved in 500 ml of
methanol and, with 2.7 g of finely powdered sodium carbonate and
4.8 g of 3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-one,
stirred at room temperature for 30 hours. The mixture is filtered
off, the filtrate is concentrated and the residue is dissolved in
70 ml of water. With ice-cooling, 1N hydrochloric acid is added
gradually until the pH is 1-2 (about 50-55 ml). The free acid
precipitates out and is filtered off with suction, washed with a
little cold water, and dried under high vacuum at 35.degree. C.
This gives 9 of molecular weight 393.48 (C.sub.18H.sub.35NO.sub.8);
MS (ESI+): 394 (M+H.sup.+); (ESI-):392 (M+H).sup.-.
[0095] b)
N-4-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)--
4-oxoazetidin-1-yl]benzyl-12-(2,3,4,5,6-pentahydroxyhexanoylamino)dodecana-
mide is prepared similarly to Example II, starting from
1-(4-aminomethylphenyl)-3-(3-hydroxy-3-phenylpropyl)-4-(4-methoxyphenyl)a-
zetidin-2-one. This gives
N-4-[3-(3-hydroxy-3-phenylpropyl)-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]-
benzyl-12-(2,3,4,5,6-pentahydroxyhexanoylamino)dodecanamide of
melting point 100.degree. C. and molecular weight 792
(C.sub.44H.sub.61N.sub.3O.sub.10); MS (ESI+): 792 (M+H.sup.+).
##STR00009##
3-[5-(tert-Butyldimethylsilanyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyl-
oxazolidin-2-one (10)
[0096] 30 g of
3-[5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyloxazolidin-2-one
are dissolved in 50 ml of DMF. 14.3 g of imidazole and 19 g of
tert-butyldimethylsilyl chloride in 25 ml of DMF are added, and the
mixture is then stirred at room temperature until the reaction has
gone to completion (2-4 h). The reaction solution is concentrated,
water is added and the mixture is extracted with ethyl acetate. The
organic phase is dried over magnesium sulfate and concentrated,
giving 10: C.sub.26H.sub.34FNO.sub.4Si (471.65) MS (ESI) 494
(M+Na)
3-[(4-Fluorophenylimino)methyl]benzonitrile (11)
[0097] 88 ml of para-fluoroaniline are added dropwise to 12 g of
meta-cyanobenzaldehyde in 60 ml of isopropanol. After 1 h at
60.degree. C., the product precipitates out. The mixture is allowed
to warm to room temperature and filtered off, and the residue is
washed with isopropanol. Drying gives 11 of m.p. 101.degree. C.
[0098] C.sub.14H.sub.9FN.sub.2 (224.24).
3-[5-(tert-Butyldimethylsilanyloxy)-5-(4-fluorophenyl)-1-(4-fluorophenylam-
ino)-2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentyl]benzonitrile
(12)
##STR00010##
[0100] At 10.degree. C., 24 ml of diisopropylethylamine are added
to 14 g of
3-[5-(tert-butyldimethyl-silanyloxy)-5-(4-fluorophenyl)pentanoyl]-4-ph-
enyloxazolidin-2-one (10) and 12.5 g of
3-[(4-fluorophenylimino)methyl]benzonitrile 11 in 200 ml of
methylene chloride, and 7.1 ml of trimethylsilyl chloride are added
dropwise. After 1 h, 3.4 ml of titanium tetrachloride are added
dropwise at -10.degree. C. The mixture is stirred at -10.degree. C.
for 3 h and then allowed to stand at -30.degree. C. for another 12
h. 8 ml of acetic acid and 140 ml of a 7% strength aqueous tartaric
acid solution are then added, and stirring is continued at room
temperature for another 2 h. 50 ml of 20% strength aqueous sodium
hydrogen sulfite solution are added, and the mixture is then
stirred for another hour and extracted with methylene chloride. The
organic phase is dried over magnesium sulfate, concentrated and
purified by silica gel chromatography (ethyl
acetate/heptane=1/3->1/1). This gives 12
[0101] C.sub.40H.sub.43F.sub.2N.sub.3O.sub.4Si (695.89) MS (ESI)
696 (M+H)
3-[3-[3-(tert-Butyldimethylsilanyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluo-
rophenyl)-4-oxoazetidin-2-yl]benzonitrile (13)
##STR00011##
[0103] Under argon, a mixture of 13 g of
3-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)-1-(4-fluorophenyla-
mino)-2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentyl]benzonitrile
12, 50 ml of bistrimethylsilylacetamide, 0.5 g of
tetrabutylammonium fluoride and 100 ml of tert-butyl methyl ether
is stirred at room temperature for 10 h. After the reaction has
ended, 5 ml of acetic acid are added slowly with ice-cooling, and
the mixture is concentrated. The residue is separated by silica gel
chromatography (ethyl acetate/heptane=1/8). This gives 13:
[0104] C.sub.31H.sub.34F.sub.2N.sub.2O.sub.2Si (532.71) MS (ESI)
555 (M+Na)
3-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-
-2-yl}-benzonitrile (14)
##STR00012##
[0106] 10 ml of 1N hydrochloric acid are added to 7.8 g of
3-[3-[3-(tert-butyldimethyl-silanyloxy)-3-(4-fluorophenyl)propyl]-(4-fluo-
rophenyl)-4-oxoazetidin-2-yl]-benzonitrile (12) in 200 ml of
methanol, and the mixture is stirred for 12 h. Aqueous sodium
bicarbonate solution is added to the reaction mixture, which is
then extracted with methylene chloride. The organic phase is dried
over magnesium sulfate, concentrated and purified by silica gel
chromatography (ethyl acetate/heptane=1/3->1/1). This gives 14:
C.sub.25H.sub.20F.sub.2N.sub.2O.sub.2 (418.45) MS (ESI) 401
(M+H--H.sub.2O)
EXAMPLE IV
4-(3-Aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-
propyl]-azetidin-2-one (15)
##STR00013##
[0108] In an autoclave, at a hydrogen pressure of 75 bar, 2.5 g of
3-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidi-
n-2-yl}benzonitrile 5 are reacted in 100 ml of ethanol and 15 ml of
concentrated ammonia with 1.0 g of Raney-Nickel for 20 h. The
reaction solution is filtered, concentrated and separated by silica
gel chromatography (methylene chloride/methanol=10/1). This gives
15: C.sub.25H.sub.24F.sub.2N.sub.2O.sub.2 (422.48) MS (ESI) 405
(M+H--H.sub.2O)
EXAMPLE V
N-3-{2-(4-Fluorophenyl)-4-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetid-
in-2-yl}-benzyl-2,3,4,5,6-pentahydroxyhexanamide (16)
##STR00014##
[0110] 25 mg of sodium carbonate are added to a solution of 100 mg
of
4-(3-aminomethyl-phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydro-
xypropyl]azetidin-2-one 6 and 46 mg of
3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-one in 5 ml of
methanol, and the mixture is stirred at room temperature until the
reaction has gone to completion. The reaction solution is filtered
and concentrated. The residue is purified by HPLC (Knauer
Eurospher-100-10-C18, water (0.1% trifluoroacetic
acid)/acetonitrile (0.1% trifluoroacetic acid)=80/20->10/90).
This gives 16: C.sub.31H.sub.34F.sub.2N.sub.2O.sub.8 (600.62) MS
(ESI) 601 (M+H)
EXAMPLE VI
[3-(3-{2-(4-Fluorophenyl)-4-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazet-
idin-2-yl}-benzylcarbamoyl)propyl]trimethylammonium
2,2,2-trifluoroacetate (17)
##STR00015##
[0112] A solution of 100 mg of
4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one (15), 64 mg of
3-carboxypropyl-trimethylammonium chloride, 93 .mu.l of
diisopropylcarbodiimide, 65 mg of hydroxybenzotriazole and 60 .mu.l
of diisopropylethylamine in 2 ml of methylene chloride is stirred
at room temperature for 12 h. Water is added, and the mixture is
extracted with methylene chloride. The organic phase is dried over
magnesium sulfate, concentrated and separated by HPLC (Knauer
Eurospher-100-10-C18, water (0.1% trifluoroacetic
acid)/acetonitrile (0.1% trifluoroacetic acid)=80/20->10/90).
This gives 17: C.sub.32H.sub.38F.sub.2N.sub.3O.sub.3 (550.67) MS
(ESI) 551 (M+H)
EXAMPLE VII
[3-(3-{2-(4-Fluorophenyl)-4-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazet-
idin-2-yl}benzylcarbamoyl)-2-hydroxypropyl]trimethylammonium
2,2,2-trifluoroacetate (18)
##STR00016##
[0114] 18 is prepared similarly to 17 starting from 100 mg of
4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one 15, 64 mg of
(3-carboxy-2-hydroxypropyl)trimethylammonium chloride, 93 .mu.l
diisopropylcarbodiimide, and 65 mg of hydroxybenzotriazole in 2 ml
of methylene chloride. Without any extraction step, the reaction
solution is concentrated and then purified by HPLC
(Merck-Hibar-Lichrospher 100-RP-18, water (0.1% trifluoroacetic
acid)/acetonitrile (0.1% trifluoroacetic acid)=80/20->10/90).
This gives 18: C.sub.32H.sub.38F.sub.2N.sub.3O.sub.4 (566.67) MS
(ESI) 567 (M+H)
EXAMPLE VIII
##STR00017##
[0115]
N-[5-(3-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]--
4-oxoazetidin-2-yl}phenylcarbamoyl)pentyl]-2,3,4,5,6-pentahydroxyhexanamid-
e (19)
[0116] 19 is prepared similarly to 18 starting from 100 mg of
4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one 15, 108 mg of
6-(2,3,4,5,6-pentahydroxyhexanoylamino)hexanoic acid, 93 .mu.l of
diisopropylcarbodiimide and 65 mg of hydroxybenzotriazole in 2 ml
of methylene chloride. This gives 10:
[0117] C.sub.37H.sub.45F.sub.2N.sub.3O.sub.9 (713.78) MS (ESI) 714
(M+H)
##STR00018##
{2-[2-(2,3,4,5,6-Pentahydroxyhexanoylamino)ethoxy]ethoxy}acetic
Acid (20)
[0118] 172 mg of sodium carbonate are added to a solution of 450 mg
of [2-(2-aminoethoxy)ethoxy]acetic acid and 318 mg of
3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-one in 10 ml of
methanol, and the mixture is stirred at room temperature until the
reaction has gone to completion. The reaction solution is filtered
and concentrated. The residue is taken up in water and acetonitrile
(1/1), resulting in the formation of 2 phases. The aqueous phase is
concentrated and contains 20:
[0119] C.sub.12H.sub.23NO.sub.10 (341.32) MS (ESI) 342 (M+H)
EXAMPLE IX
##STR00019##
[0120]
N-(2-{2-[(3-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxyprop-
yl]-4-oxoazetidin-2-yl}benzylcarbamoyl)methoxy]ethoxy}ethyl)-2,3,4,5,6-pen-
tahydroxyhexanamide (21)
[0121] 21 is prepared similarly to 18 starting from 100 mg of
4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one (15), 122 mg of
{2-[2-(2,3,4,5,6-pentahydroxyhexanoylamino)ethoxy]ethoxy}acetic
acid (20), 93 .mu.l of diisopropylcarbodiimide and 65 mg of
hydroxybenzotriazole in 2 ml of dimethylformamide. This gives 21:
C.sub.37H.sub.45F.sub.2N.sub.3O.sub.11 (745.78) MS (ESI) 746
(M+H)
##STR00020##
EXAMPLE X
N-(2-{2-[(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-o-
xoazetidin-2-yl}benzylcarbamoyl)methoxy]ethoxy}ethyl)-2,3,4,5,6-pentahydro-
xyhexanamide (22)
[0122] 22 is prepared similarly to 18 starting from 100 mg of
4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one, 122 mg of
{2-[2-(2,3,4,5,6-pentahydroxyhexanoylamino)ethoxy]ethoxy}acetic
acid 20, 93 .mu.l of diisopropylcarbodiimide and 65 mg of
hydroxybenzotriazole in 2 ml of dimethylformamide and 1 ml of
acetonitrile. This gives 22: C.sub.37H.sub.45F.sub.2N.sub.3O.sub.11
(745.78) MS (ESI) 746 (M+H)
2,3,4-Triacetoxy-1-{2-[2-(2-aminoethoxy)ethoxy]acetyl}-5-hydroxypentyl
Acetate (23)
##STR00021##
[0124] In a hydrogenation apparatus, a suspension of 1.12 g of
2,3,4-triacetoxy-1-{2-[2-(2-azido-ethoxy)ethoxy]acetyl}-5-hydroxypentyl
acetate and 1.0 g of Raney-Nickel in 100 ml of ethanol is shaken
under an atmosphere of hydrogen for 4 h. The reaction solution is
filtered and concentrated. The residue contains 23:
[0125] C.sub.20H.sub.33NO.sub.12 (479.49) MS (ESI) 480 (M+H)
##STR00022##
{2-[2-({2-[2-(3,4,5,6-Tetraacetoxy-7-hydroxy-2-oxoheptyloxy)ethoxy]ethylc-
arbamoyl}-methoxy)ethoxy]ethoxy}acetic Acid (24)
[0126] A solution of 500 mg of
2,3,4-triacetoxy-1-{2-[2-(2-aminoethoxy)ethoxy]acetyl}-5-hydroxypentyl
acetate 23, 1.15 g of [2-(2-carboxymethoxyethoxy)ethoxy]acetic
acid, 400 .mu.l of diisopropylcarbodiimide and 288 mg of
hydroxybenzotriazole in 20 ml of methylene chloride is stirred at
room temperature for 12 h. The reaction solution is concentrated
and separated by HPLC (Knauer Eurospher-100-10-C18, water (0.1%
trifluoroacetic acid)/acetonitrile (0.1% trifluoroacetic
acid)=80/20->10/90). This gives 24: C.sub.28H.sub.45NO.sub.18
(683.67) MS (ESI) 684 (M+H)
[2-({2-[2-(3,4,5,6-Tetraacetoxy-7-hydroxy-2-oxoheptyloxy)ethoxy]ethylcarba-
moyl}-methoxy)ethoxy]acetic Acid (25)
##STR00023##
[0128] 25 is prepared similarly to 24 starting from 500 mg of
2,3,4-triacetoxy-1-{2-[2-(2-aminoethoxy)ethoxy]acetyl}-5-hydroxypentyl
acetate 23, 927 mg of (2-carboxymethoxyethoxy)acetic acid, 400
.mu.l of diisopropylcarbodiimide and 288 mg of hydroxybenzotriazole
in 20 ml of methylene chloride. This gives 25:
[0129] C.sub.26H.sub.41NO.sub.17 (639.61) MS (ESI) 640 (M+H)
{2-[2-({2-[2-(3,4,5,6,7-Pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}-
-methoxy)ethoxy]ethoxy}acetic Acid (26)
##STR00024##
[0131] At room temperature, 100 .mu.l of a 5.4 M sodium methoxide
solution in methanol are added to a solution of 200 mg of
{2-[2-({2-[2-(3,4,5,6-tetraacetoxy-7-hydroxy-2-oxo-heptyloxy)ethoxy]ethyl-
carbamoyl}methoxy)ethoxy]ethoxy}acetic acid (24) in 5 ml of
methanol, and the mixture is stirred for 2 h. 1 g of Amberlite IR
120 is added to the reaction solution and the mixture is stirred
for 10 min, filtered and concentrated, giving 26:
[0132] C.sub.20H.sub.37NO.sub.14 (515.52) MS (ESI) 516 (M+H)
[2-({2-[2-(3,4,5,6,7-Pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}met-
hoxy)-ethoxy]acetic Acid (27)
##STR00025##
[0134] 27 is prepared similarly to 26 starting from 200 mg of 25.
This gives 27: C.sub.26H.sub.41N1O.sub.17 (471.46) MS (ESI) 472
(M+H)
EXAMPLE XI
N-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazeti-
din-2-yl}-benzyl)-2-{2-[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)et-
hoxy]ethyl-carbamoyl}methoxy)ethoxy]ethoxy}acetamide (28)
##STR00026##
[0136] 28 is prepared similarly to 18 starting from 62 mg of
4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one, 76 mg of
{2-[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl-
}methoxy)-ethoxy]ethoxy}acetic acid 17, 57 .mu.l of
diisopropylcarbodiimide and 40 mg of hydroxybenzotriazole in 2 ml
of dimethylformamide. This gives 19:
C.sub.45H.sub.59F.sub.2N.sub.3O.sub.14 (919.98) MS (ESI) 920
(M+H)
EXAMPLE XII
N-(3-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazeti-
din-2-yl}-benzyl)-2-{2-[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxo-heptyloxy)e-
thoxy]ethyl-carbamoyl}methoxy)ethoxy]ethoxy}acetamide (29)
##STR00027##
[0138] 29 is prepared similarly to 18 starting from 62 mg of
4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one 15, 76 mg of
{2-[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl-
}methoxy)-ethoxy]ethoxy}acetic acid 26, 57 .mu.l of
diisopropylcarbodiimide and 40 mg of hydroxybenzotriazole in 2 ml
of dimethylformamide. This gives 29:
C.sub.45H.sub.59F.sub.2N.sub.3O.sub.14 (919.98) MS (ESI) 920
(M+H)
EXAMPLE XIII
N-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazeti-
din-2-yl}-benzyl)-2-[2-({2-[2-(3,4,5,6,7-penta
hydroxy-2-oxoheptyloxy)ethoxy]-ethylcarbamoyl}-methoxy)ethoxy]acetamide
(30)
##STR00028##
[0140] 30 is prepared similarly to 18 starting from 68 mg of
4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one, 76 mg of
[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}me-
thoxy)-ethoxy]acetic acid (27), 62 .mu.l of diisopropylcarbodiimide
and 44 mg of hydroxybenzotriazole in 2 ml of dimethylformamide.
This gives 30: C.sub.43H.sub.55F.sub.2N.sub.3O.sub.14 (875.93) MS
(ESI) 876 (M+H)
EXAMPLE XIV
N-(3-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazeti-
din-2-yl}-benzyl)-2-[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethox-
y]ethylcarbamoyl}-methoxy)ethoxy]acetamide (31)
##STR00029##
[0142] 31 is prepared similarly to 18 starting from 68 mg of
4-(3-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one (15), 76 mg of
[2-({2-[2-(3,4,5,6,7-pentahydroxy-2-oxoheptyloxy)ethoxy]ethylcarbamoyl}me-
thoxy)-ethoxy]acetic acid (27), 62 .mu.l of diisopropylcarbodiimide
and 44 mg of hydroxybenzotriazole in 2 ml of dimethylformamide.
This gives 31: C.sub.43H.sub.55F.sub.2N.sub.3O.sub.14 (875.93) MS
(ESI) 876 (M+H)
EXAMPLE XV
[3-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazet-
idin-2-yl}benzylcarbamoyl)propyl]trimethylammonium Trifluoroacetate
(32)
##STR00030##
[0144] 91 mg of (3-carboxypropyl)trimethylammonium chloride are
dissolved in 5 ml of dimethylformamide, and the solution is cooled
to 0.degree. C. 0.055 ml of N-methylmorpholine, 210 mg of
4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one, 77 mg of N-hydroxybenzotriazole and 96 mg
of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride are
added successively, and the reaction solution is warmed to room
temperature and stirred for 12 h. The reaction mixture is
concentrated under reduced pressure and the residue is taken up in
sat. sodium bicarbonate solution, stirred and concentrated under
reduced pressure. Repeatedly, this residue is stirred in acetone
and the suspension is filtered. The combined filtrates are
concentrated and purified chromatographically (RP18;
acetonitrile/water 1/2, with 0.1% trifluoroacetic acid). This gives
[3-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoaze-
tidin-2-yl}benzylcarbamoyl)propyl]trimethylammonium;
trifluoroacetate of molecular weight 550.67
(C.sub.32H.sub.38F.sub.2N.sub.3O.sub.3; cation); MS (ESI): 551.24
(M+H.sup.+).
EXAMPLE XVI
##STR00031##
[0145]
Dodecyl-[3-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypr-
opyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)propyl]dimethylammonium
trifluoroacetate (33)
[0146] The compound of Example XVI is obtained like that of Example
XV, with the difference that, instead of
(3-carboxypropyl)trimethylammonium chloride,
(3-carboxypropyl)dodecyldimethylammonium chloride is used. This
gives
dodecyl-[3-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypr-
opyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)propyl]dimethylammonium
trifluoroacetate of molecular weight 703.96
(C.sub.43H.sub.59F.sub.2N.sub.3O.sub.3; cation); MS (ESI): 704.70
(M+H.sup.+).
EXAMPLE XVII
Dodecyl-[10-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]--
4-oxoazetidin-2-yl}benzylcarbamoyl)decyl]dimethylammonium
Trifluoroacetate (34)
[0147] The compound of Example XVII is obtained like that of
Example XV, with the difference that, instead of
(3-carboxypropyl)trimethylammonium chloride,
(10-carboxydecyl)dodecyldimethylammonium chloride is used. This
gives
dodecyl-[10-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxyp-
ropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)decyl]dimethylammonium
trifluoroacetate of molecular weight 803.16
(C.sub.50H.sub.74F.sub.2N.sub.3O.sub.3; cation); MS (ESI): 803.77
(M.sup.+).
EXAMPLE XVIII
##STR00032##
[0148]
Benzyl-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyph-
enyl)-4-oxoazetidin-1-yl]benzylcarbamoyl}butyl)-(2,3,4,5,6-pentahydroxyhex-
yl)ammonium Trifluoroacetate (35)
a) Methyl 5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentanoate
(36)
[0149] At room temperature, 1.37 g of
6-benzylaminohexane-1,2,3,4,5-pentanol are suspended in 30 ml of
dry dimethylformamide, 1.45 g of potassium carbonate, 0.83 g of
potassium iodide and 0.86 ml of methyl 5-bromovalerate are added
and the mixture is stirred at room temperature overnight. The next
day, the reaction mixture is filtered and the filtrate is
concentrated under reduced pressure and, for purification,
subjected to chromatography (silica gel; ethyl
acetate/methanol/water 5/1/0.1). This gives methyl
5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]-pentanoate of
molecular weight 385.46 (C.sub.19H.sub.31NO.sub.7); MS (ESI):
386.33 (M+H.sup.+).
b) 5-[Benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentanoic Acid
(37)
[0150] At room temperature, 0.46 g of methyl
5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)-amino]pentanoate is
dissolved in a mixture of 5 ml of ethanol and 5 ml of water, 0.4 g
of potassium hydroxide is added and the mixture is stirred at
80.degree. C. for 2 h. The cooled reaction mixture is then
concentrated under reduced pressure and the residue is taken up in
water, neutralized with hydrochloric acid and again concentrated.
The crude product is suspended in ethanol, the suspension is
filtered and the filtrate is concentrated under reduced pressure.
This gives 5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentanoic
acid of molecular weight 371.43 (C.sub.18H.sub.29NO.sub.7); MS
(ESI): 372.2 (M+H.sup.+).
c)
3-[5-(tert-Butyldimethylsilanyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phen-
yloxazolidin-2-one (38)
[0151] 27 g of
3-[5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyloxazolidin-2-one,
13.6 g of tert-butyldimethylsilyl chloride and 10.2 g of imidazole
are dissolved in 36 ml of dimethylformamide, and the mixture is
stirred at 60.degree. C. for 90 min. After the reaction has ended,
the mixture is dissolved in ethyl acetate and extracted twice with
water. The organic phase is dried over magnesium sulfate, filtered
and concentrated under reduced pressure. This gives
3-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)-pentanoyl]-4-pheny-
loxazolidin-2-one of molecular weight 471.65
(C.sub.26H.sub.34FNO.sub.4Si); MS (ESI): 340.28
(MH.sup.+--HOSi(CH.sub.3).sub.2C(CH.sub.3).sub.3).
d)
4-[5-(tert-Butyldimethylsilanyloxy)-5-(4-fluorophenyl)-1-(4-methoxyphen-
yl)-2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentylamino]benzonitrile
(39)
[0152] 16.2 g of
3-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyl-
-oxazolidin-2-one are dissolved in 350 ml of dichloromethane. 19.8
ml of Hunig base and 10.14 g of
4-[(4-methoxyphenylimino)methyl]benzonitrile are added, and the
solution is cooled to -10.degree. C. 85.2 ml of trimethylsilyl
triflate are added to the cooled solution, which is stirred at
-10.degree. C. for 30 min. The solution is then cooled to
-30.degree. C., and 44 ml of titanium tetrachloride solution are
added. The reaction mixture is stirred at from -30 to -40.degree.
C. for 2 h. The reaction solution is then allowed to warm to room
temperature and washed successively with 200 ml of 2N sulfuric
acid, 300 ml of 20% strength sodium hydrogensulfite solution and
sat. sodium chloride solution. The organic phase is dried over
magnesium sulfate and concentrated under reduced pressure, and the
residue is purified on silica gel using n-heptane/ethyl acetate
3/1. This gives
4-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)-1-(4-methoxyphenyl-
)-2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentylamino]benzonitrile
of molecular weight 707.93 (C.sub.41H.sub.46FN.sub.3O.sub.5Si); MS
(ESI): 590.51 (MH.sup.+--C.sub.7H.sub.5N.sub.2).
e)
4-[3-[3-(tert-Butyldimethylsilanyloxy)-3-(4-fluorophenyl)propyl]-2-(4-m-
ethoxyphenyl)-4-oxo-azetidin-1-yl]benzonitrile (40)
[0153] 13.2 g of
4-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)-1-(4-methoxyphenyl-
)-2-(2-oxo-4-phenyloxazolidine-3-carbonyl)pentylamino]benzonitrile
are dissolved in 380 ml of methyl tert-butyl ether, 18.6 ml of
N,O-bis(trimethylsilyl)acetamide and 1.86 ml of a 1 M solution of
tetrabutylammonium fluoride in tetrahydrofuran are added and the
mixture is stirred at room temperature for 2 h. After the reaction
has ended, 10 ml of acetic acid are added, the reaction mixture is
concentrated under reduced pressure and the residue is purified on
silica gel using toluene/ethyl acetate 50/1. This gives
4-[3-[3-(tert-butyldimethylsilanyloxy)-3-(4-fluorophenyl)propyl]-2-(4-met-
hoxyphenyl)-4-oxoazetidin-1-yl]benzonitrile of molecular weight
544.75 (C.sub.32H.sub.37FN.sub.2O.sub.3Si); MS (ESI): 545.56
(M+H.sup.+).
f)
4-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazet-
idin-1-yl]benzonitrile (41)
[0154] 3.5 g of
4-[3-[3-(tert-butyldimethylsilanyloxy)-3-(4-fluorophenyl)propyl]-2-(4-met-
hoxyphenyl)-4-oxoazetidin-1-yl]benzonitrile are dissolved in 65 ml
of tetrahydrofuran, 0.74 ml of acetic acid and 8.03 ml of a 1 M
solution of tetrabutylammonium fluoride in tetrahydrofuran are
added, and the mixture is stirred at room temperature for 2 h.
Another 4.82 ml of the tetrabutylammonium fluoride solution are
then added, and the mixture is stirred at reflux temperature for
another 3 h. The cooled reaction mixture is concentrated under
reduced pressure and the residue is purified chromatographically on
silica gel using n-heptane/ethyl acetate 2/1. This gives
4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxo-azeti-
din-1-yl]benzonitrile of molecular weight 430.48
(C.sub.26H.sub.23FN.sub.2O.sub.3); MS (ESI): 431.24
(M+H.sup.+).
g)
1-(4-Aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-met-
hoxy-phenyl)azetidin-2-one (42)
[0155] 1.22 g of
4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetid-
in-1-yl]benzonitrile are dissolved in 90 ml of ethanol, 10 ml of
conc. ammonia solution and an excess of Raney nickel are added and
the mixture is stirred at 60.degree. C. and a hydrogen pressure of
10 bar for 8 h. Overnight, the reaction mixture cools to room
temperature. The next day, the catalyst is separated off, the
filtrate is concentrated under reduced pressure and the residue is
purified chromatographically on silica gel using
dichloromethane/methanol/ammonia solution 10/1/0.1. This gives
1-(4-aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-metho-
xyphenyl)azetidin-2-one of molecular weight 434.51
(C.sub.26H.sub.27FN.sub.2O.sub.3); MS (ESI): 418.2
(MH.sup.+--NH.sub.3).
h)
Benzyl-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl-
)-4-oxoazetidin-1-yl]benzylcarbamoyl}butyl)-(2,3,4,5,6-pentahydroxyhexyl)a-
mmonium trifluoroacetate (35)
[0156] At room temperature, 100 mg of
5-[Benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]-pentanoic acid and
110 mg of
1-(4-aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-me-
thoxyphenyl)azetidin-2-one are dissolved in 2 ml of dry
dimethylformamide, 42 mg of N-hydroxybenzotriazole and 52 mg of
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride are
added and the mixture is stirred at room temperature overnight. The
next day, the reaction mixture is concentrated under reduced
pressure and, for purification, chromatographed on RP18 using
acetonitrile/water with 0.1% trifluoroacetic acid. This gives
benzyl-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)--
4-oxoazetidin-1-yl]benzylcarbamoyl}butyl)-(2,3,4,5,6-pentahydroxyhexyl)amm-
onium trifluoroacetate of molecular weight 787.92
(C.sub.44H.sub.54FN.sub.3O.sub.9; cation); MS (ESI): 788.70
(M+H.sup.+).
EXAMPLE XIX
##STR00033##
[0157]
N-4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-ox-
oazetidin-2-yl}benzyl-5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentana-
mide (43)
[0158] The compound of Example XIX is prepared starting from
5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentanoic acid and
4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one similarly to the compound of Example XVIII.
This gives
N-4-{1-(4-fluorophenyl)-343-(4-fluorophenyl)-3-hydroxypropyl]-4-oxo-
azetidin-2-yl}benzyl-5-[benzyl-(2,3,4,5,6-pentahydroxyhexyl)amino]pentanam-
ide of molecular weight 775.89
(C.sub.43H.sub.51F.sub.2N.sub.3O.sub.8); MS (ESI): 776.4
(M+H.sup.+).
EXAMPLE XX
##STR00034##
[0159]
N-{4-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4--
oxoazetidin-1-yl]benzyl}acetamide (44)
[0160] The compound of Example XX is prepared by reacting acetic
acid similarly to Example XVIII with
1-(4-aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-metho-
xyphenyl)azetidin-2-one. This gives
N-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoaze-
tidin-1-yl]benzyl}acetamide of molecular weight 476.55
(C.sub.28H.sub.29FN.sub.2O.sub.4); MS (ESI): 477.22
(M+H.sup.+).
EXAMPLE XXI
##STR00035##
[0161]
5-(9H-Fluoren-9-ylmethoxycarbonylamino)-5-(4-{1-(4-fluorophenyl)-3--
[3-(4-fluoro-phenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)p-
entyl]trimethyl-ammonium Chloride (45)
[0162] The compound of Example XXI is obtained similarly to the
procedure of Example XIX by reacting
4-(4-aminomethylphenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydrox-
ypropyl]azetidin-2-one with
[5-carboxy-5-(9H-fluoren-9-ylmethoxycarbonyl-amino)pentyl]trimethylammoni-
um chloride. This gives
[5-(9H-fluoren-9-ylmethoxy-carbonylamino)-5-(4-{1-(4-fluorophenyl)-3-[3-(-
4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}benzylcarbamoyl)pentyl-
]trimethylammonium chloride of molecular weight 815.99
(C.sub.49H.sub.53F.sub.2N.sub.4O.sub.5; cation); MS (ESI): 815.81
(M.sup.+).
EXAMPLE XXII
[5-Amino-5-(4-{(1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]--
4-oxoazetidin-2-yl}benzylcarbamoyl)pentyl]trimethylammonium
Chloride Hydrochloride (M.sup.+)
##STR00036##
[0164] 110 mg of the compound of Example XXI are dissolved in 2 ml
of dry dimethylformamide, and 0.1 ml of piperidine are added. The
reaction mixture is stirred at room temperature for 2 h and, after
the reaction has ended, concentrated under reduced pressure. The
residue is stirred in water, filtered off with suction and washed
with water, and the filtrate is acidified with 2 N hydrochloric
acid. The mixture is concentrated under reduced pressure and the
residue is dried under high vacuum. The crude product is suspended
in dichloromethane, the organic phase is decanted off and the
residue is taken up in methanol, concentrated under reduced
pressure and dried under high vacuum. This gives
[5-amino-5-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]--
4-oxoazetidin-2-yl}benzylcarbamoyl)-pentyl]trimethylammonium
chloride hydrochloride of molecular weight 593.74
(C.sub.34H.sub.43F.sub.2N.sub.4O.sub.3; cation); MS (ESI): 593.37
(M.sup.+).
3-[2-[(4-Bromophenyl)-(4-fluorophenylamino)methyl]-5-(tert-butyldimethylsi-
lanyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyloxazolidin-2-one
(47)
##STR00037##
[0166] 4.4 g of
3-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyl-
oxazolidin-2-one are dissolved in 40 ml of absolute
dichloromethane. 5.2 g of
(4-bromobenzylidene)-(4-fluorophenyl)amine and 8.6 ml of
ethyldiisopropylamine are added, and the solution is then cooled to
-10.degree. C. 2.94 ml of trimethylsilyl chloride are then added
dropwise, and during the addition, the temperature of the reaction
mixture is maintained below -5.degree. C. The reaction solution is
then stirred at -10.degree. C. for half an hour and then cooled to
-30.degree. C., and 1.2 ml of titanium tetrachloride are added
dropwise, the temperature being maintained between -30.degree. C.
and -15.degree. C. This gives a black reaction solution which is
stirred at -20.degree. C. for another 3 h and then allowed to warm
to 0.degree. C. In the stated order, in intervals of 10 minutes, 10
ml of glacial acetic acid, 100 ml of 7% strength aqueous tartaric
acid solution and finally 100 ml of 20% strength aqueous sodium
hydrogensulfite solution are added with stirring. The mixture is
then extracted twice with dichloromethane and the organic phase is
washed once with saturated sodium chloride solution and dried over
sodium sulfate. The solvent is removed using a rotary evaporator
and the residue is purified by column chromatography (SiO.sub.2;
ethyl acetate/heptane 1:4). The product is obtained from diethyl
ether/pentane as white crystals.
C.sub.39H.sub.43BrF.sub.2N.sub.2O.sub.4Si (749) MS (ESI):
M.sup.+
4-(4-Bromophenyl)-3-[3-(tert-butyldimethylsilanyloxy)-3-(4-fluorophenyl)pr-
opyl]-1-(4-fluorophenyl)azetidin-2-one (48)
##STR00038##
[0168] 3.34 g of
3-[2-[(4-bromophenyl)-(4-fluorophenylamino)methyl]-5-(tert-butyl-dimethyl-
silanyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyloxazolidin-2-one
are suspended in 70 ml of tert-butyl methyl ether. 3.8 ml of
bis(trimethylsilyl)acetamide and 144 mg of tributylammonium
fluoride trihydrate are then added. The reaction mixture is stirred
at room temperature overnight, and 0.7 ml of glacial acetic acid
are then added. The reaction mixture is concentrated using a rotary
evaporator and the residue is purified by column chromatography
(SiO.sub.2; ethyl acetate/heptane 1:4). The product is obtained as
a clear oil. C.sub.30H.sub.34BrF.sub.2NO.sub.2Si (586) MS (ESI):
M.sup.+-131
3-{5-(tert-Butyldimethylsilanyloxy)-5-(4-fluorophenyl)-2-[(4-fluorophenyla-
mino)-(4-hydroxyphenyl)methyl]pentanoyl}-4-phenyloxazolidin-2-one
(49)
##STR00039##
[0170] 10 g of
3-[5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)pentanoyl]-4-phenyl-
oxazolidin-2-one are dissolved in 80 ml of absolute dichlormethane.
9.12 g of 4-[(4-fluorophenylimino)methyl]phenol and 19.6 ml of
ethyldiisopropylamine are added, and the solution is then cooled to
-10.degree. C. 6.7 ml of trimethylsilyl chloride are then added
dropwise, the temperature of the reaction mixture being maintained
at below -5.degree. C. The reaction solution is stirred at
-10.degree. C. for half an hour and then cooled to -30.degree. C.,
and 2.7 ml of titanium tetrachloride are added dropwise, the
temperature being maintained between -30.degree. C. and -15.degree.
C. This gives a black reaction solution which is stirred at
-20.degree. C. for another 3 h and then allowed to warm to
0.degree. C. In the stated order, in intervals of 10 minutes, 6 ml
of glacial acetic acid, 60 ml of 7% strength aqueous tartaric acid
solution and finally 100 ml of 20% strength aqueous sodium
hydrogensulfite solution are then added with stirring. The mixture
is then extracted three times with dichloromethane and the organic
phase is washed once with saturated sodium chloride solution and
dried over sodium sulfate. The solvent is removed using a rotary
evaporator and the residue is purified by column chromatography
(SiO.sub.2; ethyl acetate/heptane 1:4). The product is obtained
from diethyl ether/pentane as white crystals.
C.sub.39H.sub.44F.sub.2N.sub.2O.sub.5Si (686) MS (ESI):
M.sup.+-241
3-[3-(tert-Butyldimethylsilanyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorop-
henyl)-4-(4-hydroxyphenyl)azetidin-2-one (50)
##STR00040##
[0172] 2.63 g of
3-{5-(tert-butyldimethylsilanyloxy)-5-(4-fluorophenyl)-2-[(4-fluorophenyl-
-amino)-(4-hydroxyphenyl)methyl]pentanoyl}-4-phenyloxazolidin-2-one
are suspended in 60 ml of tert-butyl methyl ether. 3.22 ml of
bis(trimethylsilyl)acetamide and 122 mg of tributylammonium
fluoride trihydrate are then added. The reaction mixture is stirred
at room temperature for 3 h, and 0.6 ml of glacial acetic acid are
then added. The reaction mixture is concentrated using a rotary
evaporator and the residue is purified by column chromatography
(SiO.sub.2; ethyl acetate/heptane 1:4). The product is obtained as
clear crystals. C.sub.30H.sub.35F.sub.2NO.sub.3Si (523) MS (ESI):
M.sup.+-131
[3-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazet-
idin-2-yl}phenoxy)propyl]trimethylammonium bromide (51)
##STR00041##
[0174] 210 mg of
3-[3-(tert-butyldimethylsilanyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluoro-
phenyl)-4-(4-hydroxyphenyl)azetidin-2-one are dissolved in 4 ml of
absolute acetonitrile. 170 mg of KF.alumina (1.15 mol/100 g) and
200 mg of (3-bromopropyl)-trimethylammonium bromide are then added.
The reaction mixture is stirred at room temperature for 4 h and
then filtered. The mother liquor is concentrated using a rotary
evaporator and the residue is purified using a 5 g SiO.sub.2
cartridge (dichloromethane/methanol 5:1). The product is obtained
as an oil.
[0175] C.sub.36H.sub.49BrF.sub.2N.sub.2O.sub.3Si (703) MS (ESI):
M.sup.+-80
EXAMPLE XXIII
[3-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazet-
idin-2-yl}phenoxy)propyl]trimethylammonium Bromide (52)
##STR00042##
[0177] 180 mg of
(3-{4-[3-[3-(tert-butyldimethylsilanyloxy)-3-(4-fluorophenyl)propyl]-1-(4-
-fluorophenyl)-4-oxoazetidin-2-yl]phenoxy}propyl)trimethylammonium
bromide are dissolved in 10 ml of methanol. 1 ml of a 0.1 M aqueous
HCl solution is then added, and the reaction solution is stirred at
room temperature overnight. The mixture is neutralized with dilute
aqueous sodium bicarbonate solution and concentrated using a rotary
evaporator. The residue is purified using a 10 g SiO.sub.2
cartridge (dichloromethane/methanol 5:1). The product is obtained
as a hygroscopic solid.
[0178] C.sub.30H.sub.35BrF.sub.2N.sub.2O.sub.3 (589) MS (ESI):
M.sup.+-80
[5-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-(tert-butyldimethylsilan-
yloxy)propyl]-4-oxoazetidin-2-yl}phenoxy)pentyl]trimethylammonium
Bromide (53)
##STR00043##
[0180] 370 mg of
3-[3-(tert-butyldimethylsilanyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluoro-
phenyl)-4-(4-hydroxyphenyl)azetidin-2-one are dissolved in 3 ml of
absolute acetonitrile. 300 mg of KF.alumina (1.15 mol/100 g) and
375 mg of (3-bromopentyl)-trimethylammonium bromide are then added.
The reaction mixture is stirred at room temperature overnight and
then filtered. The mother liquor is concentrated using a rotary
evaporator and the residue is purified using a 5 g SiO.sub.2
cartridge (dichloromethane/methanol 4:1). The product is obtained
as an oil.
[0181] C.sub.38H.sub.53BrF.sub.2N.sub.2O.sub.3Si (731) MS (ESI):
M.sup.+-80
EXAMPLE XXIV
[5-(4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazet-
idin-2-yl}phenoxy)pentyl]trimethylammonium Bromide (54)
##STR00044##
[0183] 548 mg of
[5-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-(isopropyldimethyl-sila-
nyloxy)propyl]-4-oxoazetidin-2-yl}phenoxy)pentyl]trimethylammonium
bromide are dissolved in 20 ml of methanol. 1 ml of a 0.1 M aqueous
HCl solution is then added, and the reaction solution is stirred at
room temperature overnight. The mixture is neutralized with dilute
aqueous sodium bicarbonate solution and concentrated using a rotary
evaporator. The residue is purified using a 10 g SiO.sub.2
cartridge (dichloromethane/methanol 5:1). The product is obtained
as a hygroscopic solid. C.sub.32H.sub.39BrF.sub.2N.sub.2O.sub.3
(617) MS (ESI): M.sup.+-80
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(4-iodobuto-
xy)-phenyl]azetidin-2-one (55)
##STR00045##
[0185] 100 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxy-ph-
enyl)azetidin-2-one are dissolved in 10 ml of absolute
dimethylformamide. 80 mg of powdered potassium carbonate and 0.2 ml
of diiodobutane are then added. The reaction solution is stirred at
room temperature overnight. Following concentration using a rotary
evaporator and oil pump vacuum at 40.degree. C., the residue is
purified using an SiO.sub.2 cartridge (n-heptane; n-heptane/ethyl
acetate 4:1). The product is obtained as an oil.
C.sub.28H.sub.28F.sub.21NO.sub.3 (591) MS (ESI): M.sup.+-18
EXAMPLE XXV
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{4-[methyl--
(2,3,4,5,6-pentahydroxyhexyl)amino]butoxy}phenyl)azetidin-2-one
(56)
##STR00046##
[0187] 100 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(4-iodobut-
oxy)phenyl]azetidin-2-one are dissolved in 5 ml of absolute
dimethylformamide. 132 mg of 6-methylaminohexane-1,2,3,4,5-pentaol
are then added, and the reaction solution is stirred at 50.degree.
C. for 2 h. After concentration using a rotary evaporator and oil
pump vacuum at 40.degree. C., the residue is purified by
preparative HPLC. The product (89 mg) is obtained as an oil.
C.sub.35H.sub.44F.sub.2N.sub.2O.sub.8 (658) MS (ESI): M.sup.+
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(5-iodopent-
yloxy)-phenyl]azetidin-2-one (57)
##STR00047##
[0189] 150 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphe-
nyl)azetidin-2-one are dissolved in 10 ml of absolute
dimethylformamide. 120 mg of powdered potassium carbonate and 0.33
ml of diiodopentane are then added. The reaction solution is
stirred at room temperature overnight. After concentration using a
rotary evaporator and oil pump vacuum at 40.degree. C., the residue
is purified using an SiO.sub.2 cartridge (n-heptane;
n-heptane/ethyl acetate 4:1). The product is obtained as an oil.
C.sub.29H.sub.30F.sub.21NO.sub.3 (605) MS (ESI): M.sup.+-18
EXAMPLE XXVI
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{5-[methyl--
(2,3,4,5,6-pentahydroxyhexyl)amino]pentyloxy}phenyl)azetidin-2-one
(58)
##STR00048##
[0191] 170 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(5-iodopen-
tyloxy)phenyl]azetidin-2-one are dissolved in 5 ml of absolute
dimethylformamide. 220 mg of 6-methylaminohexane-1,2,3,4,5-pentaol
are then added, and the reaction solution is stirred at 50.degree.
C. for 2 h. After concentration using a rotary evaporator and oil
pump vacuum at 40.degree. C., the residue is purified by
preparative HPLC. The product is obtained as an oil.
C.sub.36H.sub.46F.sub.2N.sub.2O.sub.8 (672) MS (ESI): M.sup.+
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(6-iodohexy-
loxy)-phenyl]azetidin-2-one (59)
##STR00049##
[0193] 100 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphe-
nyl)azetidin-2-one are dissolved in 10 ml of absolute
dimethylformamide. 80 mg of powdered potassium carbonate and 0.25
ml of diiodohexane are then added. The reaction solution is stirred
at room temperature overnight. After concentration using a rotary
evaporator and oil pump vacuum at 40.degree. C., the residue is
purified using an SiO.sub.2 cartridge (n-heptane; n-heptane/ethyl
acetate 4:1). The product is obtained as an oil.
C.sub.30H.sub.32F.sub.2INO.sub.3 (619) MS (ESI): M.sup.+-18
EXAMPLE XXVII
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{6-[methyl--
(2,3,4,5,6-pentahydroxyhexyl)amino]hexyloxy}phenyl)azetidin-2-one
(60)
##STR00050##
[0195] 136 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(6-iodohex-
yloxy)phenyl]azetidin-2-one are dissolved in 10 ml of absolute
dimethylformamide. 172 mg of 6-methylaminohexane-1,2,3,4,5-pentaol
are then added, and the reaction solution is stirred at 50.degree.
C. for 2.5 h. After concentration using a rotary evaporator and oil
pump vacuum at 40.degree. C., the residue is purified by
preparative HPLC. The product is obtained as an oil.
C.sub.37H.sub.48F.sub.2N.sub.2O.sub.8 (686) MS (ESI): M.sup.+
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(8-iodoocty-
loxy)-phenyl]azetidin-2-one (61)
##STR00051##
[0197] 150 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphe-
nyl)azetidin-2-one are dissolved in 10 ml of absolute
dimethylformamide. 120 mg of powdered potassium carbonate and 0.44
ml of diiodooctane are then added. The reaction solution is stirred
at room temperature overnight. After concentration using a rotary
evaporator and oil pump vacuum at 40.degree. C., the residue is
purified using an SiO.sub.2 cartridge (n-heptane;
n-heptane/ethylacetate 4:1). The product is obtained as an oil.
C.sub.32H.sub.36F.sub.21NO.sub.3 (647) MS (ESI): M.sup.+-18
EXAMPLE XXVIII
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{8-[methyl--
(2,3,4,5,6-pentahydroxyhexyl)amino]octyloxy}phenyl)azetidin-2-one
(62)
##STR00052##
[0199] 150 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(8-iodooct-
yloxy)phenyl]azetidin-2-one are dissolved in 5 ml of absolute
dimethylformamide. 180 mg of 6-methylaminohexane-1,2,3,4,5-pentaol
are then added, and the reaction solution is stirred at 50.degree.
C. for 2 h. After concentration using a rotary evaporator and oil
pump vacuum at 40.degree. C., the residue is purified by
preparative HPLC. The product is obtained as an oil.
C.sub.39H.sub.52F.sub.2N.sub.2O.sub.8 (714) MS (ESI): M.sup.+
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(10-iododec-
yloxy)-phenyl]azetidin-2-one (63)
##STR00053##
[0201] 150 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphe-
nyl)azetidin-2-one are dissolved in 10 ml of absolute
dimethylformamide. 120 mg of powdered potassium carbonate and 865
mg of diiododecane are then added. The reaction solution is stirred
at room temperature overnight. After concentration using a rotary
evaporator and oil pump vacuum at 40.degree. C., the residue is
purified using an SiO.sub.2 cartridge (n-heptane; n-heptane/ethyl
acetate 4:1). The product is obtained as an oil.
C.sub.34H.sub.40F.sub.2INO.sub.3 (675) MS (ESI): M.sup.+-18
EXAMPLE XXIX
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{10-[methyl-
-(2,3,4,5,6-pentahydroxyhexyl)amino]decyloxy}phenyl)azetidin-2-one
(64)
##STR00054##
[0203] 170 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(10-iodode-
cyloxy)phenyl]azetidin-2-one are dissolved in 5 ml of absolute
dimethylformamide. 200 mg of 6-methylaminohexane-1,2,3,4,5-pentaol
are then added, and the reaction solution is stirred at 50.degree.
C. for 2 h. After concentration using a rotary evaporator and oil
pump pressure at 40.degree. C., the residue is purified by
preparative HPLC. The product is obtained as an oil.
C.sub.41H.sub.56F.sub.2N.sub.2O.sub.8 (742) MS (ESI): M.sup.+
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{2-[2-(2-io-
doethoxy)ethoxy]ethoxy}phenyl)azetidin-2-one (65)
##STR00055##
[0205] 150 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphe-
nyl)azetidin-2-one are dissolved in 10 ml of absolute
dimethylformamide. 120 mg of powdered potassium carbonate and 0.4
ml of 1,2-bis(diiodoethoxy)ethane are then added. The reaction
solution is stirred at room temperature overnight. After
concentration using a rotary evaporator and oil pump vacuum at
40.degree. C., the residue is purified using an SiO.sub.2 cartridge
(n-heptane; n-heptane/ethylacetate 4:1). The product is obtained as
an oil. C.sub.30H.sub.32F.sub.2INO.sub.5 (651) MS (ESI):
M.sup.+-18
EXAMPLE XXX
1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-{4-[2-(2-{2-[m-
ethyl-(2,3,4,5,6-pentahydroxyhexyl)amino]ethoxy}ethoxy)ethoxy]phenyl}azeti-
din-2-one (66)
##STR00056##
[0207] 230 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-{2-[2-(2-i-
odoethoxy)ethoxy]ethoxy}phenyl)azetidin-2-one are dissolved in 5 ml
of absolute dimethylformamide. 280 mg of
6-methylaminohexane-1,2,3,4,5-pentaol are then added, and the
reaction solution is stirred at 50.degree. C. for 2 h. After
concentration using a rotary evaporator and oil pump vacuum at
40.degree. C., the residue is purified by preparative HPLC. The
product is obtained as an oil.
C.sub.37H.sub.48F.sub.2N.sub.2O.sub.10 (718) MS (ESI):
N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)hex-5-enamide (67)
##STR00057##
[0209] 1.11 g of 5-hexenoic acid are dissolved in 3 ml of absolute
methylene dichloride. 1.4 ml of thionyl chloride are then added
dropwise. The mixture is stirred at room temperature for 3 h and
then concentrated using a rotary evaporator. 1.09 g of
6-methylaminohexane-1,2,3,4,5-pentaol are suspended in 5 ml of
absolute methylene dichloride. 5-hexenoic chloride dissolved in 3
ml of absolute methylene dichloride is added dropwise, and the
mixture is then stirred at room temperature for 4 h. The resulting
precipitate is filtered off from the reaction product, the filtrate
is concentrated using a rotary evaporator and the oily crude
product is reacted further without any purification.
C.sub.13H.sub.25NO.sub.6 (291) MS (ESI): M.sup.+
N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)-6-{4-[3-[3-(tert-butyldimethylsil-
anyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]p-
henyl}hex-5-enamide (68)
##STR00058##
[0211] 110 mg of
4-(4-bromophenyl)-3-[3-(tert-butyldimethylsilanyloxy)-3-(4-fluorophenyl)p-
ropyl]-1-(4-fluorophenyl)azetidin-2-one and 136 mg of
N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)-hex-5-enamide are
initially charged in 300 .mu.l of triethylamine under argon in a
closed tube which had been heated thoroughly beforehand. After
addition of 6 mg of palladium acetate and 14 mg of
triphenylphosphine, the mixture is stirred at 100.degree. C. for 4
h. The reaction mixture is then taken up in dichloromethane,
filtered and concentrated using a rotary evaporator. Purification
of the residue using an SiO.sub.2 cartridge
(dichloromethane/methanol 20:1-5:1) gives the product.
C.sub.43H.sub.58F.sub.2N.sub.2O.sub.8Si (796)
EXAMPLE XXXI
N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)-6-(4-{1-(4-fluorophenyl)-3-[3-(4--
fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenyl)hex-5-enamide
(69)
##STR00059##
[0213] 70 mg of
N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)-6-{4-[3-[3-(tert-butyldimethylsi-
lanyloxy)-3-(4-fluorophenyl)propyl]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl]-
phenyl}hex-5-enamide are dissolved in 6 ml of methanol. 0.1 N
HCl.sub.(aq) is then added, and the mixture is stirred at room
temperature overnight. The mixture is then neutralized with 1 N
aqueous sodium hydroxide solution and concentrated using a rotary
evaporator. The residue is stirred with dichloromethane and
filtered and the mother liquor is concentrated using a rotary
evaporator. The product is obtained following purification by
preparative HPLC: C.sub.31H.sub.44F.sub.2N.sub.2O.sub.8 (682) MS
(ESI): M.sup.+-18
EXAMPLE XXXII
2-{[4-{1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazet-
idin-2-yl}phenoxy)butyl]methylamino}ethanesulfonic Acid (70)
##STR00060##
[0215] 64.5 mg of
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-[4-(4-iodobut-
oxy)phenyl]azetidin-2-one are dissolved in 3 ml of methanol. 60.7
mg of 2-methylaminoethanesulfonic acid are then dissolved in 1 ml
of water, and 30.4 mg of potassium carbonate are added. The
reaction solution is stirred at 50.degree. C. for 8 h. After
concentration using a rotary evaporator at 40.degree. C., the
residue is passed over a reverse-phase cartridge (methanol). The
resulting crude product is dissolved in hot methanol. The
precipitate formed on cooling is filtered off, and the mother
liquor is concentrated using a rotary evaporator. The product is
obtained as an oil. C.sub.31H.sub.36F.sub.2N.sub.2O.sub.6S (602) MS
(ESI): M.sup.+-18
EXAMPLE XXXIII
1-(4-Fluorophenyl)-3-[1-(4-fluorophenyl)-2-oxo-4-(4-sulfoxyphenyl)azetidin-
-3-yl]propyl Acetate (71)
##STR00061##
[0217] 120 mg (0.27 mmol) of
1-(4-fluorophenyl)-3-[1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxoazetidi-
n-3-yl]propyl acetate are dissolved in 3 ml of pyridine, and 200 mg
of Me.sub.3NSO.sub.3 complex (Aldrich) are added. The suspension is
stirred at room temperature for 30 hours. The mixture is then
diluted with 5 ml of methylene chloride/methanol/conc. ammonia
(30/5/1) and purified by flash chromatography using the same
solvent mixture. The product is obtained as an amorphous solid.
C.sub.26H.sub.23F.sub.2NO.sub.7S (531.54) MS (ESI):
M.sup.+=532.2.
EXAMPLE XXXIV
Mono-(4-{1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoaz-
etidin-2-yl}phenyl)sulfate (72)
##STR00062##
[0219] 75 mg (0.14 mmol) of
1-(4-fluorophenyl)-3-[1-(4-fluorophenyl)-2-oxo-4-(4-sulfoxy-phenyl)azetid-
in-3-yl]propyl acetate are dissolved in 2 ml of methanol, and 0.3
ml of 1 N NaOMe/MeOH is added. After 2 hours at room temperature,
the mixture is neutralized with methanolic hydrochloric acid and
concentrated. The residue is purified by flash chromatography. The
product is obtained as an amorphous solid.
C.sub.24H.sub.21F.sub.2NO.sub.6S (489.50) MS (ESI):
M.sup.+=490.2.
EXAMPLE XXXV
2,3,4,5-Tetraacetoxy-1-{3-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-met-
hoxyphenyl)-4-oxoazetidin-1-yl]benzylcarbamoyl}pentyl Acetate
(73)
##STR00063##
[0221] 112 mg (0.24 mmol) of
1-(3-aminomethylphenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-metho-
xyphenyl)azetidin-2-one are dissolved in 5 ml of methylene chloride
and 0.5 ml of triethylamine. At 0.degree. C., 0.5 g of
2,3,4-triacetoxy-1-(acetoxychlorocarbonylmethyl)butyl acetate are
added, and the mixture is allowed to thaw to room temperature.
After 30 minutes, the mixture is diluted with ethyl acetate and
then filtered through silica gel. The solvent is distilled off and
the residue is purified by flash chromatography. The product is
obtained as an amorphous solid: C.sub.42H.sub.47FN.sub.2O.sub.14
(822.84) MS (ESI): M.sup.+=823.3.
EXAMPLE XXXVI
N-3-[3-[3-(4-Fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazeti-
din-1-yl]benzyl-2,3,4,5,6-pentahydroxyhexanamide (74)
##STR00064##
[0223] 90 mg (109 .mu.mol) of
2,3,4,5-tetraacetoxy-1-{3-[3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-2-(4-m-
ethoxyphenyl)-4-oxoazetidin-1-yl]benzylcarbamoyl}pentyl acetate are
dissolved in 7 ml of methanol and 0.5 ml of 1 N NaOMe/MeOH is
added. After 2 hours at room temperature the mixture is neutralized
with methanolic hydrochloric acid and concentrated. The residue is
purified by flash chromatography. The product is obtained as an
amorphous solid. C.sub.32H.sub.37FN.sub.2O.sub.9 (612.66) MS (ESI):
M.sup.+=613.2.
EXAMPLE XXXVII
N-Methyl-N-(2,3,4,5,6-pentahydroxyhexyl)-6-(4-{3-[1-(4-fluorophenyl)-2-(4--
methoxy-phenyl)-4-oxoazetidin-3-yl]-1-hydroxypropyl}phenyl)hex-5-enamide
(75)
##STR00065##
[0225] 200 mg of
N-methyl-N-(2,3,4,5,6-pentahydroxyhexyl)hex-5-enamide and 72 mg of
3-[3-(4-bromophenyl)-3-hydroxypropyl]-1-(4-fluorophenyl)-4-(4-me-
thoxyphenyl)-azetidin-2-one are prepared analogously to the
synthesis of Example XXXI. The product is obtained as an amorphous
solid.
[0226] Using the method described below, the activity of the
compounds of the formula I according to the invention was
examined:
Effect on Cholesterol Absorption+.sup.3H-Taurocholic Acid Excretion
Using Fecal Excrement of Mice, Rats or Hamsters
[0227] NMRI mice, Wistar rats, or Golden Syrian hamsters (in groups
of n=4-6) are kept in metabolic cages, where they are fed with a
standard diet (Altromin, Lage (Lippe)). The afternoon prior to the
administration of the radioactive tracers (.sup.14C-cholesterol),
the feed is removed and the animals are adapted to grates.
[0228] Additionally, the animals are labeled s.c. with .sup.3H-TCA
(taurocholic acid) (for example 1 .mu.Ci/mouse up to 5 .mu.Ci/rat)
24 hours prior to the peroral administration of the test meal
(.sup.14C-cholesterol in Intralipid.RTM. 20, Pharmacia-Upjohn).
[0229] Cholesterol absorption test: 0.25 ml/mouse Intralipid.RTM.
20 (Pharmacia-Upjohn) ((spiked with 0.25 .mu.Ci of
.sup.14C-cholesterol in 0.1 mg of cholesterol) is administered
perorally by gavage.
[0230] Test substances are prepared separately in 0.5%
methylcellulose (Sigma)/5% Solutol (BASF, Ludwigshafen) or a
suitable vehicle.
[0231] The administration volume of the test substance is 0.5
ml/mouse. The test substance is administered immediately prior to
the test meal (Intralipid labeled with .sup.14C-cholesterol)
(cholesterol absorption test).
[0232] The feces are collected over a period of 24 h: fecal
elimination of .sup.14C-cholesterol and .sup.3H-taurocholic acid
(TCA) is determined after 24 hours.
[0233] The livers are removed and homogenized, and aliquots are
incinerated in an oximate (Model 307, Packard) to determine the
amount of .sup.14C-cholesterol which had been taken
up/absorbed.
Evaluation:
Feces Samples:
[0234] The total weight is determined, the sample is made up with
water to a defined volume and then homogenized, and an aliquot is
evaporated to dryness and incinerated in an oximate (Model 307 from
Packard for the incineration of radioactively labeled samples): the
amount of radioactive .sup.3H--H.sub.2O and .sup.14C--CO.sub.2 is
extrapolated to the amount of .sup.3H-taurocholic acid and
.sup.14C-cholesterol, respectively, that is excreted (dual isotope
technique). The ED.sub.200 values as dose from a dose-effect curve
are interpolated as those doses at which the excretion of TCA or
cholesterol is doubled, based on a control group treated at the
same time.
Liver Samples:
[0235] The amount of .sup.14C-cholesterol taken up by the liver is
based on the administered dose. The ED.sub.50 values are
interpolated from a dose-effect curve as the dose at which the
uptake of .sup.14C-cholesterol by the liver is halved (50%), based
on a control group.
[0236] The ED.sub.50 values below demonstrate the activity of the
compounds of the formula I according to the invention
TABLE-US-00002 Example No. ED.sub.50 (liver) [mg/mouse] II 0.1 III
0.003 XIII 0.3 XV 0.01 XVIII 1.0 XX 0.03 XXI 1.0 XXIV 0.3 XXV 0.3
XXX 0.1
[0237] As can be seen from the table, the compounds of the formula
I have very good cholesterol-lowering action. The compounds can
thus be used to control cholesterol concentration. Such control can
be by lowering the cholesterol concentration, or maintaining a
desired level of cholesterol concentration.
Bioabsorption:
[0238] The bioabsorption of the compounds of the formula I can be
examined using the Caco cell model (A. R. Hilgers et al., Caco-2
cell monolayers as a model for drug transport across the intestinal
mucosa, Pharm. Res. 1990, 7, 902).
[0239] Below is a bioabsorption measurement for a reference
compound:
TABLE-US-00003 Reference structure Example Apparent partition
coefficient 4.88 .times. 10.sup.-06 P.sub.app [cm/s] (according to
Lit. Hilgers) Estimated human bioabsorption 100% ##STR00066##
Reference structure: Ezetimibe
* * * * *